People with impaired kidney function have higher levels of Alzheimer’s biomarkers in their blood, but not an increased risk of dementia, according to a study published December 3,… read more.
Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology Clinical Practice,… read more.
Eisai Co., Ltd. and Biogen Inc. announced that Leqembi IQLIK, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected… read more.
Hospice care aims to bring comfort, peace, and dignity to patients at the end of life. Yet for the growing number of Americans with dementia who enter hospice,… read more.
Alzheimer’s disease (AD) is the most common neurodegenerative disease in older people, affecting up to 1 in 20 individuals aged 65 and above. In addition to environmental and… read more.
AI-based medicine will revolutionise care including for Alzheimer’s and diabetes, predicts a technology expert, but it must be accessible to all patients. Healing with Artificial Intelligence, written by technology… read more.
Roche announced that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify… read more.
Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union… read more.
Growing evidence suggests late-life mood disorders (LLMDs), such as depression and bipolar disorder, could be early warning signs of neurodegenerative diseases like dementia – even when they appear… read more.
When it comes to advanced cancer or Alzheimer’s disease, over half of doctors would consider assisted dying for themselves, but preferences seem to vary according to their jurisdiction’s… read more.
The total economic burden of Alzheimer’s disease and related dementias in the United States will reach $781 billion this year, according to new USC-led research. This is the first… read more.
Eisai Co., Ltd. and Biogen Inc. announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as a treatment for early AD (mild… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
